Cargando…
Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment
Remdesivir was approved by the U.S.A. Food and Drug administration for emergency use to interfere with the replication of SARS CoV-2 virus (the agent that causes COVID-19) in adults and children hospitalized with severe disease. The crystal structure of the metabolite of remdesivir (Monophosphate of...
Autores principales: | Jung, Lindsey S, Gund, Tamara M, Narayan, Mahesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662030/ https://www.ncbi.nlm.nih.gov/pubmed/33185784 http://dx.doi.org/10.1007/s10930-020-09942-9 |
Ejemplares similares
-
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
por: Kirchdoerfer, Robert N., et al.
Publicado: (2019) -
Transient and stabilized complexes of Nsp7, Nsp8, and Nsp12 in SARS-CoV-2 replication
por: Wilamowski, Mateusz, et al.
Publicado: (2021) -
Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2
por: Peng, Qi, et al.
Publicado: (2020) -
Identification of fragments binding to SARS-CoV-2 nsp10 reveals ligand-binding sites in conserved interfaces between nsp10 and nsp14/nsp16
por: Kozielski, Frank, et al.
Publicado: (2021) -
Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
por: Shannon, Ashleigh, et al.
Publicado: (2020)